Dexamethasone added to induction and post-remission therapy in older patients with newly diagnosed acute myeloid leukemia: a multicenter, phase II trial (DEXAML-02)

Authors

Sarah Bertoli,[1] Emilie Bérard,[2] Pierre Peterlin,[3] Romain Guieze,[4] Yohan Desbrosses,[5] Yosr Hicheri,[6] Omar Benbrahim,[7] Martin Carre,[8] Corentin Orvain,[9] Anne Banos,[10] Marc Bernard,[11] Emmanuel Gyan,[12] Alain Saad,[13] Safia Chebrek,[14] Gabrielle Roth Guepin,[15] Veronique Dorvaux,[16] Laurence Sanhes,[17] Maria Pilar Gallego-Hernanz,[18] Carole Exbrayat,[19] Laure Vincent,[20] Chantal Himberlin,[21] Célestine Simand,[22] Norbert Vey,[6] Cindy Fenoll,[23] Ariane Mineur,[23] Anne Huynh,[1] Francois Vergez,[24] Isabelle Luquet,[24] Laetitia Largeaud,[24] Eric Delabesse,[24] Arnaud Pigneux[25] and Christian Récher;[1] on behalf of the French Innovative Leukemia Organization (FILO)

[1]Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse; [2]Service d'Epidémiologie, Centre Hospitalier Universitaire de Toulouse, CERPOP, Inserm, Université Toulouse III Paul Sabatier, Toulouse; [3]Service d'Hématologie, Centre Hospitalier Universitaire de Nantes, Nantes; [4]Service d'Hématologie Clinique et de Thérapie Cellulaire, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand; [5]Service d'Hématologie, Centre Hospitalier Universitaire de Besançon, Besançon; [6]Département d'Hématologie, Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Marseille; [7]Service d'Hématologie, Centre Hospitalier d'Orléans, Orléans; [8]Service d'Hématologie, Centre Hospitalier Universitaire de Grenoble, Grenoble; [9]Maladies du Sang, CHU d'Angers, Fédération Hospitalo-Universitaire Grand-Ouest Acute Leukemia, FHU-GOAL, Université d'Angers, Inserm UMR 1307, CNRS UMR 6075, Nantes Université, CRCI2NA, Angers; [10]Service d'Hématologie, Centre Hospitalier de la Côte Basque, Bayonne; [11]Service d'Hématologie, Centre Hospitalier Universitaire de Rennes, Rennes; [12]Service d'Hématologie, Centre Hospitalier Universitaire de Tours, Tours; [13]Service d'Hématologie, Centre Hospitalier de Béziers, Béziers; [14]Service d'Onco-Hématologie, Centre Hospitalier d'Avignon, Avignon; [15]Service d'Hématologie, Centre Hospitalier Universitaire de Nancy, Nancy; [16]Service d'Hématologie, Centre Hospitalier de Metz, Metz; [17]Service d'Hématologie, Centre Hospitalier de Perpignan, Perpignan; [18]Service d'Hématologie, Centre Hospitalier Universitaire de Poitiers, Poitiers; [19]Service d'Hématologie, Clinique du Parc, Castelnau-le-Lez; [20]Service d'Hématologie, Centre Hospitalier Universitaire de Montpellier, Montpellier; [21]Service d'Hématologie, Centre Hospitalier Universitaire de Reims, Reims; [22]Service d'Hématologie, Centre Hospitalier Universitaire de Strasbourg, Strasbourg; [23]French Innovative Leukemia Organisation, Hôpital Bretonneau, Tours; [24]Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse and [25]Service d'Hématologie Clinique et de Thérapie Cellulaire, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France

Correspondence:
C. RÉCHER - recher.christian@iuct-oncopole.fr

https://doi.org/10.3324/haematol.2024.286807

Received: December 13, 2024.
Accepted: January 28, 2025.
Early view: February 6, 2025.

Supplementary Information

Dexamethasone added to induction and post-remission therapy in older patients with newly diagnosed acute myeloid leukemia: a multicenter, phase II trial (DEXAML-02). *Sarah Bertoli et al.*

Supplementary table 1: Hematologic toxicity and adverse events during induction chemotherapy*

	DEXAML-02
	N=114
Number of days with platelets < 10 x 10^9/L	
Median	10·5
IQR	1·50; 19·00
Number of days between day 1 of induction and day when ANC ≥ 0·5 x 10^9/L	
Median	26
IQR	24; 30
Number of RBC transfusions during induction	
Median	9
IQR	6; 13
Number of platelets transfusions during induction	
Median	9·5
IQR	7; 15
Number of days with fever ≥ 38 degrees C	
Median	6
IQR	3; 11
Number of days with antibiotics	
Median	23
IQR	18; 29
Infections, n (%)	
Documented infection	65 (57%)
Grade 3-4	57 (50%)
Septic shock	3 (3%)
Grade 3-4 cutaneous, n (%)	6 (5%)
Grade 3-4 mucositis, n (%)	20 (18%)
Grade 3-4 haemorrhage, n (%)	5 (4%)
Grade 3-4 nausea or diarrhea or vomiting, n (%)	10 (9%)
Grade 3-4 pain, n (%)	4 (4%)
Grade 3-4 constipation , n (%)	2 (2%)
Grade 3-4 pulmonary events, n (%)	8 (7%)
Grade 3-4 arrhythmia, n (%)	2 (2%)
Grade 3-4 other cardiac toxicity, n (%)	7 (6%)
Grade 3-4 central nervous system, n (%)	3 (3%)
Grade 3-4 peripheral nervous system, n (%)	1 (1%)
Grade 3-4 alkaline phosphatases increased, n (%)	4 (4%)
Grade 3-4 ASAT increased, n (%)	4 (4%)
Grade 3-4 ALAT increased, n (%)	5 (4%)
Grade 3-4 bilirubin increased, n (%)	7 (6%)
Grade 3-4 creatinine increased, n (%)	1 (1%)
Grade 3-4 hyperglycemia, n (%)	12 (11%)
Grade 3-4 lipase increased, n (%)	1 (1%)
Grade 3-4 amylase increased, n (%)	1 (1%)

N=number. ANC=absolute neutrophil count. IQR=inter-quartile range. RBC=red blood cell. C=Celsius. NA=not applicable.
*Investigators were requested to monitor for and report adverse events as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0). Safety reports were monitored by the sponsor.

Supplementary figure 1: Consort diagram



Supplementary figure 2: Event-free survival, relapse-free survival and overall survival in patients with *NPM1* mutations. A. Event-free survival. B. Relapse-free survival. C. Overall survival.

A



B



C